Compare ESQ & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | OMER |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 844.6M |
| IPO Year | 2017 | 2008 |
| Metric | ESQ | OMER |
|---|---|---|
| Price | $122.49 | $20.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $120.33 | $32.50 |
| AVG Volume (30 Days) | 175.4K | ★ 1.5M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | 14.20 | ★ 98.15 |
| EPS | ★ 2.89 | 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $35.15 | N/A |
| Revenue Next Year | $39.09 | $233.22 |
| P/E Ratio | $42.62 | ★ $26.14 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $92.39 | $4.06 |
| 52 Week High | $134.65 | $21.24 |
| Indicator | ESQ | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 56.90 | 62.23 |
| Support Level | $103.79 | $18.00 |
| Resistance Level | $125.40 | N/A |
| Average True Range (ATR) | 2.81 | 0.89 |
| MACD | 0.58 | 0.02 |
| Stochastic Oscillator | 72.38 | 74.58 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.